Lupin Ltd

Lupin Ltd

Lupin Ltd has received an ESG rating of 70 for FY26 from NSE Sustainability Ratings and Analytics Limited, a marginal decline from the previous year's rating of 71 due to lower Social and Governance score.

Lupin Ltd

Lupin Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities for the quarter ended September 30, 2026.

Lupin Ltd

Lupin Ltd has received US FDA approval for its Phytonadione Injectable Emulsion USP, a generic version of a product with estimated annual sales of USD 52.3 million in the US.

Lupin Ltd

Lupin Ltd has launched Formoflo-G MDI, a fixed-dose triple combination drug for COPD management, in India, following approval from the Drug Controller General of India (DCGI).

Lupin Ltd

Lupin Ltd's subsidiary, Multicare Pharmaceuticals Philippines, Inc., has completed the buyback of 30,559 shares, making it a step-down wholly owned subsidiary of the company effective October 1, 2026.

Lupin Ltd

Lupin Ltd has announced the closure of its trading window for dealing in its securities from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ending on September 30, 2026.

Lupin Ltd

Lupin Ltd has received tentative approval from the U.S. FDA for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL via the 505(b)(2) pathway. The product will be manufactured at Lupin's Somerset, New Jersey facility, leveraging the company's U.S.-based manufacturing expertise to support high-quality standards and supply reliability.

Lupin Ltd

Lupin Ltd has been assigned an ESG rating of 'Crisil ESG 69' and a Core ESG rating of 'Crisil Core ESG 65' by Crisil ESG Ratings & Analytics Ltd, placing the company in the 'Strong' category.

Lupin Ltd

Lupin Ltd has allotted 30,967 equity shares under its employee stock option plans, increasing its issued and paid-up share capital to ₹ 91,45,31,722.

Lupin Ltd

Lupin Ltd has been assigned an ESG rating of 60 by ESG Risk Assessments & Insights Limited, placing the company in the 'Adequate' category.

Lupin Ltd

Lupin Ltd has entered into an Exclusive License Agreement with Visus Therapeutics, Inc. to commercialize YUVEZZITM in the European Union, the United Kingdom, Switzerland, Norway, and Iceland.

Lupin Ltd

Lupin Ltd has announced the demise of Dr. Sofia Mumtaz, President, Legal & Compliance, Canada, ANZ & NEA Business, a Senior Management Personnel of the Company, on August 17, 2026.

Lupin Ltd

Lupin Ltd has received final approval from the U.S. FDA for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45 mg and 17.8 mg, as bioequivalent to Wakix for the indications in the approved labeling.

Lupin Ltd

Lupin Ltd reported a record quarter with total revenues from operations and EBITDA exceeding INR 8,000 crores and INR 2,400 crores, respectively, for the first time in its history. The company announced a 16th consecutive quarter of YoY growth, with ex-U.S. organic revenue growth of 20% plus YoY and double-digit growth in all key markets, including India, Other Developed Markets, and Other Emerging Markets.

Lupin Ltd

Lupin Ltd has received approval from the US FDA for its Abbreviated New Drug Application for Sodium Zirconium Cyclosilicate for Oral Suspension, which is indicated for the treatment of hyperkalemia in adults.

Lupin Ltd

Lupin Ltd has announced its participation in several analyst/institutional investors meets, including Equirus Annual India Conference, Motilal Oswal - 22nd Annual Global Investor Conference, and Antique Healthcare Investor Conference, among others. The events are scheduled to take place between August 13 and September 1, 2026. The company has informed that the presentation to be made at the events will be in line with the presentation already available on the company's website.

Lupin Ltd

Lupin Ltd has published the unaudited financial results for the quarter ended June 30, 2026, with a revenue of ₹82,768.9, ₹74,746.6, and ₹62,683.4 for the respective periods, and a net profit of ₹14,169.8, ₹14,686.7, and ₹12,214.6 for the respective periods.

Lupin Ltd

Lupin Ltd has made available the audio recording of its Q1 FY27 earnings call on its website.

Lupin Ltd

Lupin Ltd has announced its Q1 FY27 results, with strong revenue growth and healthy EBITDA margins. The company has launched several new products, including Azilsartan Medoxomil, Ranibizumab, and Luforbec, and has received approvals for its products in various markets, including the US, China, and Europe.

Lupin Ltd

Lupin Ltd's Q1 FY2027 results show strong revenue growth with healthy EBITDA margins. The company launched several new products, including Azilsartan Medoxomil and Ranibizumab, and received approvals from US FDA and EMA. Lupin's India business grew 13.9% YoY, leveraging its chronic leadership position.